Metabolic Rivalry and Immune Signaling in the Carcinogenic Cellular Niche: Challenges and Therapeutic Advances

Neoplastic Microenvironment is a key factor influencing cancer Proliferation, spread, and therapeutic outcomes by mediating interactions between malignant and immune cells. One of the most significant aspects of these interactions is metabolic competition, wherein cancer cells alter their Cellular metabolic mechanisms—including anaerobic glycolysis, lipid oxidation, and amino acid utilization—to gain a survival advantage over immune cells. This metabolic reprogramming results in the accumulation of immunosuppressive byproducts like lactate, which impair the role of CTLs and NK cells in orchestrating tumor-directed immune responses evasion. The metabolic heterogeneity within the TME adds another layer of complexity, as tumors develop adaptive mechanisms to withstand hypoxia and nutrient deprivation, while immune cells face metabolic stress that leads to dysfunction and exhaustion. Immunotherapies, particularly Immune-modulating drugs targeting PD-1 and CTLA-4 receptors, aim to rejuvenate T-cell responses but often face challenges due to tumor-induced metabolic suppression, featuring mitochondrial dysregulation and surplus ROS production. Addressing these metabolic constraints through targeted interventions offers promising avenues to enhance immune responses and improve cancer treatment outcomes. A deeper understanding of tumor metabolism may lead to innovative therapeutic strategies aimed at disrupting tumor-mediated immune suppression while restoring immune cell functionality.